Roles/NNS
of/IN
Oncogenic/JJ
Long/JJ
Non-coding/JJ
RNAs/NNS
in/IN
Cancer/NN
Development/NN
./.
====================
Long/JJ
non-coding/JJ
RNAs/NNS
(/(
lncRNAs/NNS
)/)
are/VBP
classified/VBN
as/IN
RNAs/NNS
that/DT
are/VBP
longer/RBR
than/IN
200/CD
nucleotides/NNS
and/CC
can/MD
not/RB
be/VB
translated/VBN
into/IN
protein/NN
./.
====================
Several/JJ
studies/NNS
have/VBP
demonstrated/VBN
that/IN
lncRNAs/NNS
are/VBP
directly/RB
or/CC
indirectly/RB
involved/VBN
in/IN
a/DT
variety/NN
of/IN
biological/JJ
processes/NNS
and/CC
in/IN
the/DT
regulation/NN
of/IN
gene/NN
expression/NN
./.
====================
In/IN
addition/NN
,/,
lncRNAs/NNS
have/VBP
important/JJ
roles/NNS
in/IN
many/JJ
diseases/NNS
including/VBG
cancer/NN
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
abnormal/JJ
expression/NN
of/IN
lncRNAs/NNS
is/VBZ
observed/VBN
in/IN
several/JJ
human/JJ
solid/JJ
tumors/NNS
./.
====================
Several/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
many/JJ
lncRNAs/NNS
can/MD
function/VB
as/IN
oncogenes/NNS
in/IN
cancer/NN
development/NN
through/IN
the/DT
induction/NN
of/IN
cell/NN
cycle/NN
progression/NN
,/,
cell/NN
proliferation/NN
and/CC
invasion/NN
,/,
anti-apoptosis/JJ
,/,
and/CC
metastasis/NN
./.
====================
Oncogenic/JJ
lncRNAs/NNS
have/VBP
the/DT
potential/JJ
to/TO
become/VB
promising/VBG
biomarkers/NNS
and/CC
might/MD
be/VB
potent/JJ
prognostic/JJ
targets/NNS
in/IN
cancer/NN
therapy/NN
./.
====================
However/RB
,/,
the/DT
biological/JJ
and/CC
molecular/JJ
mechanisms/NNS
of/IN
lncRNA/JJ
involvement/NN
in/IN
tumorigenesis/NN
have/VBP
not/RB
yet/RB
been/VBN
fully/RB
elucidated/VBN
./.
====================
This/DT
review/NN
summarizes/VBZ
studies/NNS
on/IN
the/DT
regulatory/JJ
and/CC
functional/JJ
roles/NNS
of/IN
oncogenic/JJ
lncRNAs/NNS
in/IN
the/DT
development/NN
and/CC
progression/NN
of/IN
various/JJ
types/NNS
of/IN
cancer/NN
./.
====================
Upon/IN
completion/NN
of/IN
the/DT
Human/JJ
Genome/NN
Project/JJ
,/,
it/PRP
was/VBD
revealed/VBN
that/IN
only/RB
2/CD
%/NN
of/IN
the/DT
human/JJ
genome/NN
including/VBG
protein-coding/VBG
genes/NNS
[/(
1/CD
]/)
./.
====================
In/IN
the/DT
past/NN
,/,
non-coding/JJ
RNAs/NNS
(/(
ncRNAs/NNS
)/)
were/VBD
deemed/VBN
so-called/JJ
useless/NN
or/CC
‘/NN
junk/NN
’/CD
DNA/NN
./.
====================
But/CC
,/,
as/IN
a/DT
result/NN
of/IN
the/DT
Encyclopedia/NN
of/IN
DNA/NN
Elements/NNS
(/(
ENCODE/NN
)/)
project/VBP
,/,
it/PRP
was/VBD
found/VBN
that/IN
ncRNAs/NNS
have/VBP
specific/JJ
functions/NNS
in/IN
a/DT
variety/NN
of/IN
biological/JJ
processes/NNS
[/(
2/CD
]/)
./.
====================
Moreover/RB
,/,
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
98/CD
%/NN
of/IN
ncRNAs/NNS
are/VBP
involved/VBN
in/IN
various/JJ
cellular/JJ
functions/NNS
including/VBG
chromatin/NN
remodeling/NN
,/,
transcription/NN
,/,
alternative/JJ
splicing/NN
and/CC
translational/JJ
regulation/NN
./.
====================
In/IN
addition/NN
,/,
there/EX
are/VBP
several/JJ
types/NNS
of/IN
ncRNAs/NNS
including/VBG
small/JJ
non-coding/JJ
RNAs/NNS
(/(
sncRNAs/NNS
)/)
,/,
microRNAs/NNS
(/(
miRNAs/NNS
)/)
,/,
and/CC
small/JJ
nucleolar/JJ
RNAs/NNS
./.
====================
Recently/RB
,/,
it/PRP
was/VBD
reported/VBN
long/JJ
non-coding/JJ
RNAs/NNS
(/(
lncRNAs/NNS
)/)
that/WDT
were/VBD
different/JJ
from/IN
sncRNAs/NNS
[/(
3/CD
]/)
./.
====================
The/DT
classification/NN
standard/JJ
for/IN
sncRNAs/NNS
and/CC
lncRNAs/NNS
is/VBZ
based/VBN
on/IN
nucleotide/NN
(/(
nt/NNS
)/)
length/NN
,/,
and/CC
the/DT
length/NN
criterion/NN
for/IN
sncRNAs/NNS
was/VBD
less/RBR
than/IN
200/CD
nt/NNS
while/IN
the/DT
length/NN
of/IN
lncRNAs/NNS
was/VBD
more/RBR
than/IN
200/CD
nt/NNS
[/(
4/CD
]/)
./.
====================
Accumulated/VBN
clues/NNS
have/VBP
been/VBN
reported/VBN
that/IN
lncRNAs/NNS
have/VBP
important/JJ
roles/NNS
in/IN
many/JJ
biological/JJ
processes/NNS
such/JJ
as/IN
cell/NN
growth/NN
and/CC
differentiation/NN
,/,
chromatin/NN
composition/NN
,/,
and/CC
the/DT
regulation/NN
of/IN
gene/NN
expression/NN
by/IN
directly/RB
or/CC
indirectly/RB
participating/VBG
in/IN
transcription/NN
and/CC
translation/NN
,/,
indicating/VBG
that/IN
lncRNAs/NNS
could/MD
act/VB
as/IN
functional/JJ
genes/NNS
[/(
5/CD
]/)
./.
====================
Thus/RB
,/,
there/EX
are/VBP
many/JJ
efforts/NNS
conducted/VBN
by/IN
many/JJ
oncologists/NNS
to/TO
identify/VB
and/CC
analyze/VB
lncRNAs/NNS
as/IN
novel/JJ
functional/JJ
genes/NNS
responsible/JJ
for/IN
tumorigenesis/NN
and/CC
cancer/NN
development/NN
./.
====================
It/PRP
has/VBZ
been/VBN
revealed/VBN
that/IN
some/DT
of/IN
lncRNAs/NNS
act/VBP
as/IN
oncogenes/NNS
highly/RB
associated/VBN
with/IN
the/DT
hallmarks/NNS
of/IN
cancer/NN
such/JJ
as/IN
cell/NN
cycle/NN
progression/NN
,/,
anti-apoptosis/JJ
,/,
angiogenesis/NN
,/,
and/CC
metastasis/NN
[/(
6–8/CD
]/)
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
discuss/VBP
the/DT
roles/NNS
of/IN
lncRNAs/NNS
in/IN
biological/JJ
processes/NNS
and/CC
describe/VBP
the/DT
lncRNA-mediated/JJ
signaling/NN
pathways/NNS
involved/VBN
in/IN
cancers/NNS
,/,
with/IN
a/DT
focus/NN
on/IN
oncogenic/JJ
lncRNAs/NNS
./.
====================
Based/VBN
on/IN
the/DT
location/NN
and/CC
orientation/NN
on/IN
the/DT
chromosome/NN
,/,
lncRNAs/NNS
are/VBP
subdivided/VBN
as/IN
intergenic/JJ
lncRNAs/NNS
,/,
intronic/JJ
lncRNAs/NNS
,/,
bidirectional/JJ
lncRNAs/NNS
,/,
sense/NN
overlapping/VBG
lncRNAs/NNS
,/,
and/CC
antisense/JJ
RNAs/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
9/CD
,/,
10/CD
]/)
./.
====================
Briefly/RB
,/,
an/DT
intergenic/JJ
lncRNA/NN
locates/NNS
between/IN
two/CD
protein-coding/VBG
genes/NNS
more/RBR
than/IN
1/CD
kb/NN
away/NN
from/IN
each/DT
other/JJ
./.
====================
An/DT
intronic/JJ
lncRNA/NN
is/VBZ
placed/VBN
on/IN
the/DT
intron/NN
region/NN
of/IN
a/DT
protein/NN
coding/VBG
gene/NN
in/IN
either/CC
sense/NN
or/CC
antisense/JJ
direction/NN
./.
====================
A/DT
biodirectional/JJ
lncRNA/NN
is/VBZ
oriented/VBN
from/IN
the/DT
opposite/JJ
direction/NN
within/IN
1/CD
kb/NN
of/IN
the/DT
promoter/NN
for/IN
the/DT
protein-coding/VBG
gene/NN
./.
====================
In/IN
particular/JJ
,/,
when/WRB
a/DT
protein-coding/JJ
gene/NN
is/VBZ
transcribed/VBN
,/,
a/DT
biodirectional/JJ
lncRNA/NN
counterpart/NN
tends/NNS
to/TO
be/VB
transcribed/VBN
as/IN
well/RB
./.
====================
It/PRP
suggests/VBZ
that/IN
they/PRP
might/MD
share/VB
regulatory/JJ
factors/NNS
for/IN
the/DT
transcription/NN
./.
====================
A/DT
sense/NN
overlapping/VBG
lncRNA/NN
overlaps/VBZ
with/IN
a/DT
protein-coding/JJ
gene/NN
on/IN
the/DT
same/JJ
DNA/NN
strand/NN
for/IN
its/PRP$
transcription/NN
./.
====================
Since/IN
this/DT
type/NN
of/IN
lncRNA/JJ
extensively/RB
lacks/VBZ
the/DT
open/JJ
reading/NN
frame/NN
for/IN
the/DT
translation/NN
,/,
it/PRP
can/MD
be/VB
distinguished/VBN
from/IN
a/DT
transcript/NN
variant/JJ
of/IN
the/DT
protein-coding/VBG
mRNAs/NNS
./.
====================
An/DT
antisense/JJ
lncRNA/NN
can/MD
be/VB
transcribed/VBN
from/IN
the/DT
antisense/JJ
DNA/NN
strand/NN
of/IN
a/DT
protein-coding/JJ
gene/NN
./.
====================
Despite/IN
several/JJ
types/NNS
of/IN
lncRNAs/NNS
,/,
they/PRP
are/VBP
highly/RB
probable/JJ
to/TO
have/VB
been/VBN
transcribed/VBN
by/IN
RNA/NN
polymerase/NN
II/CD
,/,
capping/VBG
,/,
splicing/NN
,/,
and/CC
polyadenylation/NN
[/(
11/CD
]/)
./.
====================
They/PRP
are/VBP
also/RB
controlled/VBN
by/IN
transcription/NN
activators/NNS
and/CC
repressors/NNS
./.
====================
However/RB
,/,
it/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
lncRNAs/NNS
have/VBP
limited/VBN
coding/VBG
potential/JJ
./.
====================
LncRNAs/NNS
have/VBP
different/JJ
roles/NNS
in/IN
nucleus/NN
and/CC
cytoplasm/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
lncRNAs/NNS
in/IN
the/DT
nucleus/NN
function/NN
as/IN
chromatin/NN
remodeling/NN
and/CC
transcription/NN
guides/NNS
and/CC
are/VBP
active/JJ
in/IN
the/DT
regulation/NN
of/IN
transcription/NN
factors/NNS
(/(
TFs/NNS
)/)
and/CC
TF-associated/JJ
factors/NNS
,/,
as/IN
well/RB
as/IN
the/DT
regulation/NN
of/IN
pre-mRNA/JJ
splicing/NN
and/CC
miRNA/JJ
processing/NN
[/(
12/CD
]/)
./.
====================
LncRNAs/NNS
in/IN
the/DT
cytoplasm/NN
function/NN
as/IN
competing/VBG
endogenous/JJ
RNAs/NNS
(/(
ceRNAs/NNS
)/)
acting/VBG
as/IN
molecular/JJ
sponges/NNS
for/IN
miRNAs/NNS
,/,
targeting/VBG
proteins/NNS
to/TO
regulate/VB
their/PRP$
expression/NN
,/,
and/CC
suppressing/VBG
translation/NN
by/IN
targeting/VBG
mRNAs/NNS
[/(
13/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
their/PRP$
various/JJ
roles/NNS
in/IN
cells/NNS
,/,
lncRNAs/NNS
are/VBP
also/RB
involved/VBN
in/IN
various/JJ
human/JJ
diseases/NNS
including/VBG
cardiovascular/JJ
diseases/NNS
,/,
autoimmune/JJ
diseases/NNS
,/,
neurodegenerative/JJ
disorders/NNS
,/,
and/CC
psychiatric/JJ
disorders/NNS
[/(
10/CD
,/,
14/CD
,/,
15/CD
]/)
./.
====================
In/IN
particular/JJ
,/,
lncRNAs/NNS
are/VBP
reported/VBN
to/TO
be/VB
closely/RB
associated/VBN
with/IN
tumorigenesis/NN
[/(
8/CD
]/)
./.
====================
Many/JJ
lncRNAs/NNS
act/VBP
as/IN
oncogenic/JJ
genes/NNS
in/IN
the/DT
development/NN
of/IN
cancer/NN
through/IN
the/DT
regulation/NN
of/IN
metastasis/NN
,/,
cell/NN
death/NN
suppression/NN
,/,
and/CC
cell/NN
growth/NN
,/,
as/IN
well/RB
they/PRP
affect/VBP
the/DT
DNA/NN
damage/NN
response/NN
through/IN
their/PRP$
relationships/NNS
with/IN
various/JJ
genes/NNS
[/(
16/CD
]/)
./.
====================
In/IN
the/DT
next/JJ
section/NN
,/,
we/PRP
demonstrate/VBP
the/DT
functions/NNS
of/IN
cancer-related/JJ
oncogenic/JJ
lncRNAs/NNS
in/IN
lung/NN
cancer/NN
,/,
colorectal/JJ
cancer/NN
,/,
glioblastoma/NN
,/,
and/CC
breast/NN
cancer/NN
./.
====================
Non-small/JJ
cell/NN
lung/NN
cancer/NN
====================
Lung/NN
cancer/NN
is/VBZ
the/DT
leading/VBG
cause/VBP
of/IN
cancer-related/JJ
deaths/NNS
in/IN
the/DT
world/NN
[/(
17/CD
]/)
./.
====================
Eighty-five/JJ
percent/NN
of/IN
lung/NN
cancer/NN
is/VBZ
classified/VBN
as/IN
non-small/JJ
cell/NN
lung/NN
cancer/NN
(/(
NSCLC/NN
)/)
and/CC
the/DT
remaining/VBG
15/CD
%/NN
is/VBZ
categorized/VBN
as/IN
small-cell/JJ
lung/NN
cancer/NN
[/(
18/CD
]/)
./.
====================
Approximately/RB
70/CD
%/NN
of/IN
NSCLC/NN
patients/NNS
are/VBP
diagnosed/VBN
at/IN
an/DT
advanced/JJ
cancer/NN
metastatic/JJ
state/NN
and/CC
their/PRP$
5-year/JJ
probability/NN
of/IN
survival/NN
is/VBZ
approximately/RB
14/CD
%/NN
[/(
19/CD
]/)
./.
====================
Various/JJ
lncRNAs/NNS
have/VBP
been/VBN
implicated/VBN
in/IN
NSCLC/NN
including/VBG
,/,
PVT1/NN
,/,
LINC00152/NN
,/,
HOTAIR/NN
,/,
H19/NN
,/,
UPAT/NN
,/,
HOXD-AS1/NN
,/,
LINC00339/NN
,/,
and/CC
MLAT/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
lncRNA/JJ
plasmacytoma/NN
variant/JJ
translocation/NN
1/CD
(/(
PVT1/NN
)/)
was/VBD
first/JJ
described/VBN
in/IN
2013/CD
in/IN
human/JJ
colorectal/JJ
cancer/NN
./.
====================
PVT1/NN
,/,
located/JJ
at/IN
8q24/NN
,/,
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
regulated/VBN
in/IN
the/DT
biological/JJ
processes/NNS
of/IN
various/JJ
cancer/NN
types/NNS
,/,
including/VBG
liver/NN
,/,
colon/NN
,/,
and/CC
ovarian/JJ
cancers/NNS
[/(
20–22/CD
]/)
./.
====================
Recent/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
PVT1/NN
expression/NN
is/VBZ
positively/RB
associated/VBN
with/IN
NSCLC/NN
aggressiveness/NN
[/(
23/CD
]/)
./.
====================
PVT1/NN
promotes/VBZ
cell/NN
growth/NN
,/,
cancer/NN
cell/NN
invasion/NN
and/CC
anti-apoptosis/NN
by/IN
acting/VBG
as/IN
a/DT
ceRNA/JJ
to/TO
sponge/VB
miR-195/NN
or/CC
miR-497/NN
[/(
24/CD
,/,
25/CD
]/)
./.
====================
In/IN
addition/NN
,/,
PVT1/NN
upregulates/VBZ
matrix/NN
metalloproteinase/NN
9/CD
(/(
MMP9/NN
)/)
by/IN
acting/VBG
as/IN
a/DT
ceRNA/JJ
to/TO
suppress/VB
miR-200a/b/NN
activity/NN
,/,
thereby/RB
increasing/VBG
cancer/NN
cell/NN
invasion/NN
capacity/NN
through/IN
increased/VBN
MMP9/NN
expression/NN
[/(
25/CD
]/)
./.
====================
The/DT
oncogenic/JJ
roles/NNS
of/IN
PVT1/NN
could/MD
be/VB
supported/VBN
by/IN
the/DT
bioinformatics/NNS
analyses/NNS
based/VBN
on/IN
the/DT
Oncomine/NN
database/NN
(/(
http/NN
:/:
//www.oncomine.org//JJ
)/)
demonstrating/VBG
that/IN
PVT1/NN
expression/NN
was/VBD
significantly/RB
upregulated/VBN
in/IN
lung/NN
adenocarcinomas/NNS
(/(
2.232-/CD
and/CC
4.293-fold/RB
change/NN
)/)
compared/VBN
to/TO
the/DT
corresponding/JJ
normal/JJ
tissues/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
[/(
26/CD
,/,
27/CD
]/)
./.
====================
Overexpression/NN
of/IN
long/JJ
intergenic/JJ
ncRNA/NN
152/CD
(/(
LINC00152/NN
)/)
promotes/VBZ
the/DT
development/NN
of/IN
NSCLC/NN
./.
====================
One/CD
study/NN
reported/VBD
that/IN
LINC00152/NN
can/MD
upregulate/VB
the/DT
expression/NN
of/IN
epidermal/JJ
growth/NN
factor/NN
receptor/NN
(/(
EGFR/NN
)/)
,/,
which/WDT
acts/VBZ
to/TO
upregulate/VB
tumor/NN
cell/NN
proliferation/NN
by/IN
increasing/VBG
the/DT
activation/NN
of/IN
the/DT
phosphoinositide/NN
3-kinase/NN
(/(
PI3K/NN
)/)
/Akt/NN
pathway/NN
[/(
28/CD
]/)
./.
====================
Moreover/RB
,/,
increased/VBD
expression/NN
of/IN
LINC00152/NN
increases/VBZ
the/DT
protein/NN
levels/NNS
of/IN
fibronectin/NN
and/CC
vimentin/NN
and/CC
decreases/VBZ
the/DT
protein/NN
levels/NNS
of/IN
p21/NN
,/,
indicating/VBG
that/IN
the/DT
expression/NN
of/IN
LINC00152/NN
is/VBZ
associated/VBN
with/IN
cancer/NN
cell/NN
invasion/NN
and/CC
anti-apoptosis/NN
./.
====================
This/DT
study/NN
was/VBD
supported/VBN
by/IN
another/DT
effort/NN
conducting/VBG
an/DT
RNA/NN
immunoprecipitation/NN
assay/NN
with/IN
LINC00152/NN
and/CC
EGFR/NN
[/(
29/CD
]/)
./.
====================
It/PRP
revealed/VBD
that/IN
LINC00152/NN
could/MD
bind/VB
to/TO
EGFR/NN
(/(
the/DT
potential/JJ
peptide/NN
sequence/NN
of/IN
EGFR/NN
for/IN
binding/VBG
target/NN
:/:
MHLPSPTDSNFYR/NN
)/)
and/CC
might/MD
allow/VB
EGFR/NN
to/TO
be/VB
phosphorylated/VBN
for/IN
its/PRP$
activation/NN
./.
====================
In/IN
addition/NN
,/,
an/DT
increase/NN
in/IN
LINC00152/NN
expression/NN
can/MD
decrease/VB
the/DT
level/NN
of/IN
tumor/NN
suppressor/NN
interleukin-24/NN
by/IN
binding/VBG
to/TO
enhancer/NN
of/IN
zeste/JJ
homolog/NN
2/CD
(/(
EZH2/NN
)/)
,/,
which/WDT
was/VBD
supported/VBN
by/IN
an/DT
RNA/NN
immunoprecipitation/NN
assay/NN
[/(
30/CD
]/)
./.
====================
It/PRP
indicated/VBD
that/IN
LINC00152/NN
expression/NN
can/MD
promote/VB
cell/NN
cycle/NN
progression/NN
and/CC
cell/NN
proliferation/NN
./.
====================
Colorectal/JJ
cancer/NN
====================
Colorectal/JJ
cancer/NN
(/(
CRC/NN
)/)
is/VBZ
the/DT
third/JJ
leading/VBG
cause/VBP
of/IN
morbidity/NN
and/CC
,/,
after/IN
lung/NN
cancer/NN
,/,
the/DT
second/JJ
leading/VBG
cause/VBP
of/IN
cancer-related/JJ
deaths/NNS
in/IN
the/DT
world/NN
[/(
17/CD
]/)
./.
====================
In/IN
recent/JJ
decades/NNS
,/,
many/JJ
studies/NNS
of/IN
CRC/NN
have/VBP
revealed/VBN
several/JJ
tumor-associated/JJ
molecular/JJ
markers/NNS
,/,
such/JJ
as/IN
PI3K/NN
,/,
BRAF/NN
,/,
and/CC
KRAS/JJ
[/(
31/CD
]/)
./.
====================
Despite/IN
advances/NNS
in/IN
treatment/NN
therapies/NNS
,/,
survival/NN
rates/NNS
have/VBP
remained/VBN
less/RBR
than/IN
50/CD
%/NN
due/JJ
to/TO
insufficient/JJ
therapeutic/JJ
tolerance/NN
[/(
32/CD
]/)
./.
====================
The/DT
lncRNAs/NNS
that/DT
have/VBP
been/VBN
associated/VBN
with/IN
CRC/NN
include/VBP
SNHG1/NN
,/,
GAPLINC/NN
,/,
TP73-AS1/NN
,/,
CASC15/NN
,/,
SOX21-AS1/NN
,/,
ZEB1-AS1/NN
,/,
DLEU1/NN
,/,
and/CC
LINC00174/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Small/JJ
nucleolar/JJ
RNA/NN
host/NN
gene/NN
1/CD
(/(
SNHG1/NN
)/)
is/VBZ
reported/VBN
to/TO
improve/VB
cancer/NN
cell/NN
proliferation/NN
and/CC
invasion/NN
in/IN
CRC/NN
./.
====================
In/IN
addition/NN
,/,
SNHG1/NN
can/MD
function/VB
as/IN
a/DT
sponge/JJ
of/IN
miR-145/JJ
leading/VBG
to/TO
block/VB
the/DT
expression/NN
of/IN
miR-145/JJ
[/(
33/CD
]/)
,/,
which/WDT
has/VBZ
targets/NNS
associated/VBN
with/IN
tumorigenesis/NN
including/VBG
insulin-like/JJ
growth/NN
factor/NN
1/CD
receptor/NN
and/CC
p21-activated/JJ
kinase/NN
4/CD
[/(
34/CD
]/)
./.
====================
Moreover/RB
,/,
expression/NN
of/IN
SNHG1/NN
promotes/VBZ
activation/NN
of/IN
the/DT
Wnt/β-catenin/NN
signaling/NN
pathway/NN
by/IN
direct/JJ
binding/NN
to/TO
and/CC
inhibiting/VBG
miR-302/372/373/520/NN
,/,
leading/VBG
to/TO
CRC/NN
cell/NN
proliferation/NN
[/(
35/CD
,/,
36/CD
]/)
./.
====================
The/DT
oncogenic/JJ
roles/NNS
of/IN
SNHG1/NN
could/MD
be/VB
supported/VBN
by/IN
the/DT
bioinformatics/NNS
analyses/NNS
based/VBN
on/IN
the/DT
colon/NN
and/CC
rectum/FW
adenocarcinoma/NN
gene/NN
expression/NN
data/NNS
conducted/VBD
by/IN
The/DT
Cancer/NN
Genome/NNP
Atlas/IN
deposited/JJ
in/IN
Oncomine/NN
database/NN
demonstrating/VBG
that/IN
SNHG1/NN
expression/NN
was/VBD
significantly/RB
upregulated/VBN
in/IN
cecum/JJ
adenocarcinomas/NNS
(/(
2.697-fold/RB
change/NN
)/)
,/,
rectal/JJ
adenocarcinomas/NNS
(/(
3.333-fold/RB
change/NN
)/)
,/,
colon/NN
adenocarcinomas/NNS
(/(
2.806-fold/RB
change/NN
)/)
,/,
and/CC
colon/NN
mucinous/JJ
adenocarcinomas/NNS
(/(
2.241-fold/RB
change/NN
)/)
compared/VBN
to/TO
the/DT
corresponding/JJ
normal/JJ
tissues/NNS
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
The/DT
expression/NN
of/IN
gastric/JJ
adenocarcinoma/NN
predictive/JJ
long/JJ
intergenic/JJ
non-coding/JJ
(/(
GAPLINC/NN
)/)
is/VBZ
upregulated/VBN
in/IN
CRC/NN
./.
====================
GAPLINC/NN
can/MD
directly/RB
bind/VBP
to/TO
PTB-associated/JJ
splicing/NN
factor/NN
and/CC
non-POU-domain-containing/JJ
octamer-binding/JJ
protein/NN
supported/VBD
by/IN
RNA/NN
pull-down/JJ
assays/NNS
,/,
which/WDT
lead/VBP
to/TO
upregulation/NN
of/IN
SNAI2/NN
expression/NN
and/CC
subsequent/JJ
induction/NN
of/IN
cancer/NN
cell/NN
invasion/NN
[/(
37/CD
]/)
./.
====================
In/IN
addition/NN
,/,
GAPLINCR/NN
can/MD
downregulate/VB
miR-34a/NNS
by/IN
acting/VBG
as/IN
a/DT
ceRNA/JJ
,/,
resulting/VBG
in/IN
increased/VBN
levels/NNS
of/IN
a/DT
proto-oncogene/NN
c-MET/NN
(/(
a/DT
target/NN
of/IN
miR-34a/JJ
)/)
,/,
which/WDT
is/VBZ
associated/VBN
with/IN
invasion/NN
by/IN
and/CC
migration/NN
of/IN
cancer/NN
cells/NNS
[/(
38/CD
]/)
./.
====================
Glioblastoma/NN
====================
Glioma/NN
,/,
which/WDT
is/VBZ
present/JJ
in/IN
more/RBR
than/IN
30/CD
%/NN
of/IN
brain/NN
cancer/NN
patients/NNS
,/,
is/VBZ
one/CD
of/IN
the/DT
cancers/NNS
with/IN
the/DT
poorest/JJ
prognosis/NN
[/(
39/CD
]/)
./.
====================
Despite/IN
the/DT
advancements/NNS
in/IN
technology/NN
and/CC
therapeutic/JJ
approaches/NNS
for/IN
glioma/NN
treatment/NN
,/,
its/PRP$
prognosis/NN
is/VBZ
poor/JJ
and/CC
recurrence/NN
of/IN
glioma/NN
progression/NN
might/MD
be/VB
unavoidable/JJ
[/(
40/CD
]/)
./.
====================
Gliomas/NNS
are/VBP
sub-divided/VBN
into/IN
grades/NNS
II–IV/NN
with/IN
glioblastomas/NNS
(/(
GBM/NN
)/)
,/,
with/IN
the/DT
highest/JJS
grade/NN
,/,
having/VBG
a/DT
high/JJ
risk/NN
of/IN
invasion/NN
and/CC
recurrence/NN
[/(
41/CD
,/,
42/CD
]/)
./.
====================
Despite/IN
many/JJ
studies/NNS
investigating/VBG
strategies/NNS
for/IN
surgery/NN
,/,
radiotherapy/NN
,/,
and/CC
chemotherapy/NN
of/IN
GBM/NN
,/,
the/DT
survival/NN
period/NN
for/IN
patients/NNS
with/IN
GBM/NN
is/VBZ
short/JJ
[/(
43/CD
]/)
./.
====================
The/DT
lncRNAs/NNS
that/DT
have/VBP
been/VBN
associated/VBN
with/IN
GBM/NN
include/VBP
NEAT1/NN
,/,
DANCR/NN
,/,
lncHERG/NN
,/,
SNHG7/NN
,/,
MNX1-AS1/NN
,/,
MCM3AP-AS1/NN
,/,
and/CC
LINC01446/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
The/DT
expression/NN
of/IN
nuclear/JJ
paraspeckle/NN
assembly/NN
transcript/NN
1/CD
(/(
NEAT1/NN
)/)
is/VBZ
higher/JJR
in/IN
GBM/NN
cells/NNS
than/IN
in/IN
normal/JJ
brain/NN
cells/NNS
./.
====================
NEAT1/NN
act/VBP
as/IN
a/DT
sponge/NN
of/IN
miR-449b-5p/JJ
,/,
leading/VBG
to/TO
downregulation/NN
of/IN
the/DT
miRNA/NN
expression/NN
[/(
44/CD
]/)
./.
====================
Consequently/RB
,/,
the/DT
expression/NN
of/IN
c-Met/NN
,/,
which/WDT
has/VBZ
a/DT
tumorigenic/JJ
role/NN
and/CC
is/VBZ
a/DT
molecular/JJ
target/NN
of/IN
miR-449b-5p/JJ
,/,
is/VBZ
increased/VBN
./.
====================
Another/DT
study/NN
has/VBZ
presented/VBN
that/IN
NEAT1/NN
can/MD
also/RB
act/VBP
as/IN
a/DT
ceRNA/JJ
for/IN
miR-132/NN
inhibition/NN
,/,
which/WDT
lead/VBP
to/TO
increase/VB
of/IN
oncogene/NN
SOX2/NN
expression/NN
and/CC
subsequent/JJ
induction/NN
of/IN
cell/NN
proliferation/NN
,/,
invasion/NN
,/,
and/CC
migration/NN
in/IN
glioma/NN
cells/NNS
[/(
45/CD
]/)
./.
====================
The/DT
oncogenic/JJ
roles/NNS
of/IN
NEAT1/NN
could/MD
be/VB
supported/VBN
by/IN
the/DT
bioinformatics/NNS
analyses/NNS
based/VBN
on/IN
the/DT
Oncomine/NN
database/NN
demonstrating/VBG
that/IN
NEAT1/NN
expression/NN
was/VBD
significantly/RB
upregulated/VBN
in/IN
GBM/NN
(/(
5.286-/CD
and/CC
4.887-fold/RB
change/NN
)/)
compared/VBN
to/TO
the/DT
corresponding/JJ
normal/JJ
brain/NN
tissues/NNS
(/(
Fig/NN
./.
====================
5/CD
)/)
[/(
46/CD
,/,
47/CD
]/)
./.
====================
Differentiation/NN
antagonizing/VBG
non-protein/JJ
coding/VBG
RNA/NN
(/(
DANCR/NN
)/)
is/VBZ
another/DT
oncogenic/JJ
lncRNA/NN
present/JJ
in/IN
GBM/NN
cells/NNS
./.
====================
DANCR/NN
is/VBZ
reported/VBN
to/TO
inhibit/VB
several/JJ
tumor-suppressive/JJ
miRNAs/NNS
including/VBG
miR-33b-5p/JJ
,/,
miR-1-3p/JJ
,/,
miR-206/NN
,/,
and/CC
miR-613/NN
by/IN
functioning/VBG
as/IN
a/DT
ceRNA/JJ
[/(
48/CD
]/)
./.
====================
Inhibition/NN
of/IN
these/DT
miRs/NNS
by/IN
DANCR/NN
is/VBZ
associated/VBN
with/IN
activation/NN
of/IN
AXL/PI3K/Akt/NF-κB/NN
signaling/NN
./.
====================
Another/DT
study/NN
has/VBZ
demonstrated/VBN
that/IN
DANCR/NN
can/MD
activate/VB
Wnt/β-catenin/NN
signaling/NN
although/IN
further/RBR
study/NN
for/IN
identification/NN
of/IN
potential/JJ
DANCR/NN
targets/NNS
on/IN
Wnt/β-catenin/NN
signaling/NN
would/MD
be/VB
required/VBN
[/(
49/CD
]/)
./.
====================
These/DT
effects/NNS
of/IN
DANCR/NN
is/VBZ
responsible/JJ
for/IN
cell/NN
proliferation/NN
,/,
anti-apoptosis/JJ
,/,
and/CC
cell/NN
migration/NN
functions/NNS
,/,
and/CC
,/,
as/IN
a/DT
consequence/NN
,/,
contributes/VBZ
to/TO
chemoresistance/VB
in/IN
GBM/NN
therapy/NN
./.
====================
Breast/NN
cancer/NN
====================
Breast/NN
cancer/NN
(/(
BC/NN
)/)
is/VBZ
the/DT
most/JJS
frequently/RB
diagnosed/VBN
cancer/NN
and/CC
the/DT
leading/VBG
cause/VBP
of/IN
cancer/NN
death/NN
in/IN
women/NNS
[/(
17/CD
]/)
./.
====================
Despite/IN
many/JJ
studies/NNS
into/IN
therapeutic/JJ
technologies/NNS
and/CC
strategies/NNS
for/IN
BC/NN
in/IN
recent/JJ
decades/NNS
,/,
BC/NN
remains/VBZ
among/IN
the/DT
leading/VBG
causes/VBZ
of/IN
morbidity/NN
and/CC
mortality/NN
worldwide/NN
[/(
50/CD
]/)
./.
====================
The/DT
lncRNAs/NNS
associated/VBN
with/IN
BC/NN
include/VBP
MALAT1/NN
,/,
CCAT2/NN
,/,
PRLB/NN
,/,
SUMO1P3/NN
,/,
LINC00518/NN
,/,
ITGB2-AS1/NN
,/,
ARNILA/NN
,/,
and/CC
PANDAR/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
Metastasis-associated/JJ
lung/NN
adenocarcinoma/NN
transcript/NN
1/CD
(/(
MALAT1/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
oncogenic/JJ
lncRNAs/NNS
related/JJ
to/TO
BC/NN
./.
====================
Overexpression/NN
of/IN
MALAT1/NN
activates/VBZ
cyclin-dependent/JJ
kinase/NN
4/CD
(/(
CDK4/NN
)/)
by/IN
functioning/VBG
as/IN
a/DT
ceRNA/JJ
for/IN
inhibition/NN
of/IN
miR-124/NN
expression/NN
[/(
51/CD
]/)
./.
====================
Since/IN
CDK4/NN
is/VBZ
a/DT
major/JJ
regulator/NN
of/IN
the/DT
cell/NN
cycle/NN
and/CC
E2F1/NN
is/VBZ
a/DT
downstream/JJ
target/NN
of/IN
CDK4/NN
,/,
CDK4/E2F1/NN
signaling/NN
activated/VBN
by/IN
MALAT1/NN
is/VBZ
closely/RB
associated/VBN
with/IN
cell/NN
cycle/NN
progression/NN
and/CC
cancer/NN
cell/NN
proliferation/NN
./.
====================
Another/DT
study/NN
has/VBZ
presented/VBN
that/WDT
MALAT1/NN
can/MD
also/RB
act/VBP
as/IN
a/DT
ceRNA/JJ
to/TO
sponge/VB
miR-204/NN
[/(
52/CD
]/)
./.
====================
Decreased/VBN
miR-204/NN
can/MD
upregulate/VB
the/DT
expression/NN
of/IN
zinc/NN
finger/NN
E-box/NN
binding/NN
homeobox/NN
2/CD
,/,
thereby/RB
increasing/VBG
epithelial-mesenchymal/JJ
transition/NN
capacity/NN
and/CC
BC/NN
cell/NN
invasion/NN
./.
====================
The/DT
oncogenic/JJ
roles/NNS
of/IN
MALAT1/NN
could/MD
be/VB
supported/VBN
by/IN
the/DT
bioinformatics/NNS
analyses/NNS
based/VBN
on/IN
the/DT
Oncomine/NN
database/NN
demonstrating/VBG
that/IN
MALAT1/NN
expression/NN
was/VBD
significantly/RB
upregulated/VBN
in/IN
invasive/JJ
ductal/JJ
breast/NN
carcinomas/NNS
(/(
2.600-/CD
and/CC
2.166-fold/RB
change/NN
)/)
compared/VBN
to/TO
the/DT
corresponding/JJ
normal/JJ
breast/NN
tissues/NNS
(/(
Fig/NN
./.
====================
6/CD
)/)
[/(
53/CD
,/,
54/CD
]/)
./.
====================
Colon/NN
cancer-associated/JJ
transcript/NN
2/CD
(/(
CCAT2/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
lncRNAs/NNS
which/WDT
expression/NN
is/VBZ
higher/JJR
in/IN
BC/NN
cells/NNS
than/IN
in/IN
normal/JJ
breast/NN
cells/NNS
./.
====================
CCAT2/NN
can/MD
decrease/VB
tumor/NN
suppressor/NN
p15/NN
by/IN
direct/JJ
interaction/NN
with/IN
EZH2/NN
,/,
which/WDT
supported/VBD
by/IN
an/DT
RNA/NN
immunoprecipitation/NN
assay/NN
[/(
55/CD
]/)
./.
====================
Based/VBN
on/IN
this/DT
effect/NN
of/IN
CCAT2/NN
,/,
overexpressed/VBN
CCAT2/NN
can/MD
indirectly/RB
increase/VBP
cell/NN
cycle-associated/JJ
proteins/NNS
including/VBG
cyclin/NN
D1/NN
,/,
cyclin/NN
E1/NN
,/,
and/CC
CDK4/NN
,/,
thereby/RB
promoting/VBG
BC/NN
cell/NN
proliferation/NN
./.
====================
Other/JJ
study/NN
have/VBP
reported/VBN
that/IN
upregulated/VBN
CCAT2/NN
can/MD
induce/VB
cell/NN
growth/NN
,/,
invation/NN
,/,
metastasis/NN
,/,
and/CC
anti-apoptosis/JJ
in/IN
BC/NN
cells/NNS
through/IN
its/PRP$
ability/NN
to/TO
regulate/VB
the/DT
transforming/VBG
growth/NN
factor/NN
β/SMAD/NN
signaling/VBG
and/CC
Wnt/β-catenin/NN
signaling/VBG
although/IN
specific/JJ
targets/NNS
of/IN
CCAT2/NN
on/IN
both/DT
signaling/VBG
pathways/NNS
have/VBP
remained/VBN
unclear/JJ
[/(
56/CD
,/,
57/CD
]/)
./.
====================
Initially/RB
,/,
ncRNAs/NNS
,/,
which/WDT
do/VBP
not/RB
encode/VB
proteins/NNS
,/,
were/VBD
referred/VBN
to/TO
as/IN
noise/RB
or/CC
junk/NN
DNA/NN
./.
====================
However/RB
,/,
interest/VBP
in/IN
ncRNAs/NNS
increased/VBD
following/VBG
the/DT
completion/NN
of/IN
the/DT
Human/JJ
Genome/NN
Project/NN
./.
====================
Since/IN
then/RB
,/,
the/DT
study/NN
of/IN
ncRNAs/NNS
has/VBZ
gradually/RB
become/VBP
a/DT
central/JJ
research/NN
area/NN
in/IN
RNA/NN
biology/NN
./.
====================
As/IN
the/DT
amount/NN
of/IN
research/NN
on/IN
ncRNAs/NNS
continues/NNS
to/TO
grow/VB
,/,
the/DT
importance/NN
of/IN
the/DT
non-protein-coding/JJ
part/NN
of/IN
the/DT
human/JJ
genome/NN
has/VBZ
been/VBN
highlighted/VBN
./.
====================
In/IN
addition/NN
,/,
with/IN
the/DT
revealing/VBG
of/IN
several/JJ
important/JJ
roles/NNS
of/IN
lncRNAs/NNS
in/IN
vivo/FW
,/,
interest/VBP
in/IN
lncRNAs/NNS
has/VBZ
increased/VBN
./.
====================
Research/NN
into/IN
the/DT
roles/NNS
of/IN
lncRNAs/NNS
has/VBZ
presented/VBN
a/DT
new/JJ
direction/NN
for/IN
research/NN
into/IN
tumorigenic/JJ
mechanisms/NNS
and/CC
cancer/NN
therapies/NNS
./.
====================
In/IN
general/JJ
,/,
an/DT
increase/NN
in/IN
lncRNAs/NNS
expression/NN
is/VBZ
observed/VBN
to/TO
be/VB
highly/RB
correlated/VBD
to/TO
the/DT
incidence/NN
of/IN
cancer/NN
./.
====================
In/IN
addition/NN
,/,
upregulated/VBN
lncRNAs/NNS
contribute/VBP
to/TO
the/DT
promotion/NN
of/IN
many/JJ
biological/JJ
processes/NNS
associated/VBN
with/IN
cancer/NN
development/NN
such/JJ
as/IN
cell/NN
cycle/NN
progression/NN
as/IN
well/RB
as/IN
cell/NN
proliferation/NN
,/,
invasion/NN
,/,
metastasis/NN
,/,
and/CC
chemoresistance/NN
./.
====================
Despite/IN
the/DT
findings/NNS
of/IN
many/JJ
lncRNA-related/JJ
studies/NNS
,/,
there/EX
are/VBP
still/RB
many/JJ
obstacles/NNS
to/TO
fully/RB
elucidating/VBG
the/DT
functions/NNS
of/IN
lncRNAs/NNS
./.
====================
Regardless/RB
,/,
future/JJ
lncRNA/NN
studies/NNS
are/VBP
expected/VBN
to/TO
reveal/VB
and/CC
describe/VBP
the/DT
regulatory/JJ
networks/NNS
and/CC
molecular/JJ
characteristics/NNS
of/IN
human/JJ
cancers/NNS
./.
====================
Elucidation/NN
of/IN
the/DT
relationships/NNS
between/IN
oncogenic/JJ
lncRNAs/NNS
and/CC
tumorigenesis/NN
may/MD
be/VB
helpful/JJ
for/IN
in/IN
the/DT
development/NN
of/IN
deeper/JJ
insights/NNS
into/IN
cancer/NN
prevention/NN
and/CC
treatment/NN
./.
====================
Illustrations/NNS
for/IN
the/DT
classification/NN
of/IN
long/JJ
non-coding/JJ
RNAs/NNS
./.
====================
The/DT
long/JJ
non-coding/JJ
RNA/NN
(/(
lncRNA/NN
)/)
functions/VBZ
in/IN
the/DT
nucleus/NN
and/CC
the/DT
cytoplasm/NN
./.
====================
Expression/NN
levels/NNS
of/IN
PVT1/NN
in/IN
non-small/JJ
cell/NN
lung/NN
cancers/NNS
./.
====================
Datasets/NNS
obtained/VBN
from/IN
Oncomine/NN
demonstrated/VBD
that/IN
lung/NN
adenocarcinomas/NNS
significantly/RB
expressed/VBN
high/JJ
levels/NNS
of/IN
PVT1/NN
compared/VBN
to/TO
the/DT
normal/JJ
counterparts/NNS
./.
====================
(/(
A/NN
)/)
Fold/JJ
change/NN
=/JJ
2.232/CD
,/,
p/NN
=/JJ
6.13/CD
×/CD
10−8/CD
[/(
26/CD
]/)
./.
====================
(/(
B/NN
)/)
Fold/JJ
change/NN
=/JJ
4.293/CD
,/,
p/NN
=/JJ
1.45/CD
×/CD
10−5/CD
[/(
27/CD
]/)
./.
====================
PVT1/NN
,/,
plasmacytoma/NN
variant/JJ
translocation/NN
1/CD
./.
====================
Expression/NN
levels/NNS
of/IN
SNHG1/NN
in/IN
colorectal/JJ
cancers/NNS
./.
====================
Datasets/NNS
obtained/VBN
from/IN
Oncomine/NN
demonstrated/VBD
that/IN
cecum/JJ
adenocarcinomas/NNS
(/(
A/DT
)/)
(/(
fold/JJ
change/NN
=/JJ
2.697/CD
,/,
p/NN
=/JJ
5.22/CD
×/RB
10−14/CD
)/)
,/,
rectal/JJ
adenocarcinomas/NNS
(/(
B/NN
)/)
(/(
fold/JJ
change/NN
=/JJ
3.333/CD
,/,
p/NN
=/JJ
1.08/CD
×/RB
10−21/CD
)/)
,/,
colon/NN
adenocarcinomas/NNS
(/(
C/NN
)/)
(/(
fold/JJ
change/NN
=/JJ
2.806/CD
,/,
p/NN
=/JJ
2.31/CD
×/RB
10−19/CD
)/)
,/,
and/CC
colon/NN
mucinous/JJ
adenocarcinomas/NNS
(/(
D/NN
)/)
(/(
fold/JJ
change/NN
=/JJ
2.241/CD
,/,
p/NN
=/JJ
1.10/CD
×/RB
10−10/CD
)/)
significantly/RB
expressed/VBN
high/JJ
levels/NNS
of/IN
PVT1/NN
compared/VBN
to/TO
the/DT
normal/JJ
counterparts/NNS
./.
====================
SNHG1/NN
,/,
small/JJ
nucleolar/JJ
RNA/NN
host/NN
gene/NN
1/CD
;/:
PVT1/NN
,/,
plasmacytoma/NN
variant/JJ
translocation/NN
1/CD
./.
====================
Expression/NN
levels/NNS
of/IN
NEAT1/NN
in/IN
glioblastomas/NNS
./.
====================
Datasets/NNS
obtained/VBN
from/IN
Oncomine/NN
demonstrated/VBD
that/IN
GBM/NN
significantly/RB
expressed/VBN
high/JJ
levels/NNS
of/IN
NEAT1/NN
compared/VBN
to/TO
the/DT
normal/JJ
counterparts/NNS
./.
====================
(/(
A/NN
)/)
Fold/JJ
change/NN
=/JJ
5.286/CD
,/,
p/NN
=/JJ
3.18/CD
×/CD
10−14/CD
[/(
46/CD
]/)
./.
====================
(/(
B/NN
)/)
Fold/JJ
change/NN
=/JJ
4.887/CD
,/,
p/NN
=/JJ
1.15/CD
×/CD
10−11/CD
[/(
47/CD
]/)
./.
====================
NEAT1/NN
,/,
nuclear/JJ
paraspeckle/NN
assembly/NN
transcript/NN
1/CD
;/:
GBM/NN
,/,
glioblastomas/NNS
./.
====================
Expression/NN
levels/NNS
of/IN
MALAT1/NN
in/IN
breast/NN
cancers/NNS
./.
====================
Datasets/NNS
obtained/VBN
from/IN
Oncomine/NN
demonstrated/VBD
that/IN
invasive/JJ
ductal/JJ
breast/NN
carcinomas/NNS
significantly/RB
expressed/VBN
high/JJ
levels/NNS
of/IN
MALAT1/NN
compared/VBN
to/TO
the/DT
normal/JJ
counterparts/NNS
./.
====================
(/(
A/NN
)/)
Fold/JJ
change/NN
=/JJ
2.600/CD
,/,
p/NN
=/JJ
2.45/CD
×/CD
10−6/CD
[/(
53/CD
]/)
./.
====================
(/(
B/NN
)/)
Fold/JJ
change/NN
=/JJ
2.166/CD
,/,
p/NN
=/JJ
6.14/CD
×/CD
10−4/CD
[/(
54/CD
]/)
./.
====================
MALAT1/NN
,/,
metastasis-associated/JJ
lung/NN
adenocarcinoma/NN
transcript/NN
1/CD
./.
====================
Oncogenic/JJ
lncRNAs/NNS
in/IN
non-small/JJ
cell/NN
lung/NN
cancers/NNS
====================
Oncogenic/JJ
lncRNAs/NNS
in/IN
colorectal/JJ
cancers/NNS
====================
Oncogenic/JJ
lncRNAs/NNS
in/IN
glioblastomas/NNS
====================
Oncogenic/JJ
lncRNAs/NNS
in/IN
breast/NN
cancers/NNS
====================
